Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 1.00 |
| ▸ | RAB9A | P51151 | 5/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | KDM1A | O60341 | 2/20 | 0.74 |
| ▸ | MAOA | P21397 | 1/20 | 0.74 |
| ▸ | MAOB | P27338 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.67 |
| ▸ | MITF | O75030 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | ASF1A | Q9Y294 | 1/20 | 0.67 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.67 |
| ▸ | CA12 | O43570 | 1/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 1/20 | 0.65 |
| ▸ | CA9 | Q16790 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salinazid SCHEMBL1173696 | 1.00 | NPC1 (1.00) | NPC1RAB9AL3MBTL1HTTKDM1A | |
| Salinazid SCHEMBL564003 | 1.00 | NPC1 (1.00) | NPC1RAB9AL3MBTL1HTTKDM1A | |
| Salinazid SCHEMBL29444172 | 1.00 | NPC1 (1.00) | NPC1RAB9AL3MBTL1HTTKDM1A | |
| Salinazid SCHEMBL15755893 | 0.99 | NPC1 (0.97) | NPC1RAB9AL3MBTL1HTTKDM1A | |
| Salicylaldehyde Benzoyl Hydrazone SCHEMBL30193248 | 0.88 | KDM1A (0.82) | NPC1RAB9AL3MBTL1HTTKDM1A | |
| Salicylaldehyde Benzoyl Hydrazone SCHEMBL414977 | 0.88 | KDM1A (0.82) | NPC1RAB9AL3MBTL1HTTKDM1A | |
| Salicylaldehyde Benzoyl Hydrazone SCHEMBL6638532 | 0.88 | KDM1A (0.82) | NPC1RAB9AL3MBTL1HTTKDM1A | |
| Salicylaldehyde Benzoyl Hydrazone SCHEMBL414978 | 0.88 | KDM1A (0.82) | NPC1RAB9AL3MBTL1HTTKDM1A | |
| SCHEMBL14712666 | 0.85 | KDM1A (1.00) | NPC1RAB9AL3MBTL1HTTKDM1A | |
| SCHEMBL19283316 | 0.85 | KDM1A (1.00) | NPC1RAB9AL3MBTL1HTTKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 322 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017080761-A1 | MICROMECHANICAL COMPONENT, METHOD FOR PRODUCING A MICROMECHANICAL COMPONENT, AND METHOD FOR TILTING AND/OR LINEARLY ADJUSTING AN ADJUSTABLE ELEMENT INSIDE A SURROUNDING HERMETIC ENCAPSULATION | ROBERT BOSCH GMBH (DE) | 2017-05-18 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-2560634-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | Piramal Enterprises Limited (IN) | 2013-02-27 | — | — | EP | claimed |
| EP-1588403-B1 | LOW-GIDL MOSFET STRUCTURE AND METHOD FOR FABRICATION | IBM (US) | 2012-03-28 | — | — | EP | claimed |
| WO-2011132171-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | WO | claimed |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-20090306412-A1 | 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS | ANTIBE THERAPEUTICS INC. (CA) | 2009-12-10 | — | — | US | claimed |
| US-20090131342-A1 | Nitrosated and/or nitrosylated compounds, compositions and methods of use | NITROMED, INC. (US) | 2009-05-21 | — | — | US | claimed |
| EP-2041108-A1 | 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS | Antibe Therapeutics Inc. (US) | 2009-04-01 | — | — | EP | claimed |
| EP-1252133-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2002-10-30 | — | — | EP | claimed |
| CN-1356981-A | Pharmaceutical compounds | NICOX SA (FR) | 2002-07-03 | — | — | CN | claimed |
| EP-1192129-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2002-04-03 | — | — | EP | claimed |
| EP-1169294-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2002-01-09 | — | — | EP | claimed |
| EP-1169298-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2002-01-09 | — | — | EP | claimed |
| WO-2001054691-A1 | NITRATE SALTS OF ANTIMICROBIAL AGENTS | NICOX, S.A. (FR) | 2001-08-02 | — | — | WO | claimed |
| WO-2001012584-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2001-02-22 | — | — | WO | claimed |
| WO-2000061549-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061541-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061537-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306412-A1 | 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS | HRH4, HRH2, HNMT | NPC1 1709/4885RAB9A 3009/4885L3MBTL1 2932/4885 |
| US-20090131342-A1 | Nitrosated and/or nitrosylated compounds, compositions and methods of use | LTC4S, LTB4R2, LTB4R | NPC1 500/4885RAB9A 3511/4885L3MBTL1 3525/4885 |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | NOS2, NOS1, NOS3 | NPC1 1629/4885RAB9A 3125/4885L3MBTL1 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.